COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

Mastocytosis is a neoplasm characterized by an accumulation of mast cells in various organs and increased risk for severe anaphylaxis in patients with concomitant allergies. Coronavirus disease 2019 (COVID-19) is a pandemic that is associated with a relatively high rate of severe lung disease and mo...

Descripción completa

Detalles Bibliográficos
Autores: Bonadonna, Patrizia, Brockow, Knut, Niedoszytko, Marek, Oude Elberink, Hanneke, Akin, Cem, Nedoszytko, Boguslaw, Butterfield, Joseph H., Álvarez-Twose, Iván, Sotlar, Karl, Schwaab, Juliana, Jawhar, Mohamad, Castells, Mariana, Sperr, Wolfgang R., Hermine, Olivier, Gotlib, Jason, Zanotti, Roberta, Reiter, Andreas, Broesby-Olsen, Sigurd, Bindslev-Jensen, Carsten, Schwartz, Lawrence B., Horny, Hans-Peter, Radia, Deepti, Triggiani, Massimo, Sabato, Vito, Carter, Melody C., Siebenhaar, Frank, Orfao, Alberto, Grattan, Clive, Metcalfe, Dean D., Arock, Michel, Gülen, Theo, Hartmann, Karin, Valent, Peter
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/239245
Acceso en línea:http://hdl.handle.net/10261/239245
Access Level:acceso abierto
Palabra clave:Vaccine
COVID-19
Mastocytosis
Mast cell diseases
Adverse reaction to medications
Hypersensitivity reactions
Descripción
Sumario:Mastocytosis is a neoplasm characterized by an accumulation of mast cells in various organs and increased risk for severe anaphylaxis in patients with concomitant allergies. Coronavirus disease 2019 (COVID-19) is a pandemic that is associated with a relatively high rate of severe lung disease and mortality. The mortality is particularly high in those with certain comorbidities and increases with age. Recently, several companies have developed an effective vaccination against COVID-19. Although the reported frequency of severe side effects is low, there is an emerging discussion about the safety of COVID-19 vaccination in patients with severe allergies and mastocytosis. However, even in these patients, severe adverse reactions are rare. We therefore recommend the broad use of COVID-19 vaccination in patients with mastocytosis on a global basis. The only well-established exception is a known or suspected allergy against a constituent of the vaccine. Safety measures, including premedication and postvaccination observation, should be considered in all patients with mastocytosis, depending on the individual personal risk and overall situation in each case. The current article provides a summary of published data, observations, and expert opinion that form the basis of these recommendations.

Similares en LA Referencia